secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-283351
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Q1 net loss $9.0M; BB-301 100% responder rate; FDA Fast Track; raised $100M
--------------------------------------------------------------------------------

- Net loss of $9.0M ($0.22/sh) vs $5.1M ($0.18) YoY; total expenses $9.8M, up from $5.8M.
- All 6 Cohort 1 patients in BB-301 Phase 1b/2a met formal response criteria (100% responder rate).
- FDA granted Fast Track Designation for BB-301; first Cohort 2 patient dosed in Q4 2025.
- Raised ~$100M in oversubscribed equity offering at $13.50/sh; cash $94.5M at Sep 30.
- Appointed Sharon Mates (ex-CEO Intra-Cellular Therapies) to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525283351/0001193125-25-283351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525283351/d811784d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-283351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer